Shikari® Ravulizumab ELISA Kit

$1,570.00

The Shikari® Ravulizumab ELISA Kit is intended for the quantitative determination of Ravulizumab in human serum and plasma. The Shikari® Ravulizumab ELISA Kit is for Research Use Only and not for diagnostic procedures.

Ravulizumab is a potent and long-acting complement C5 inhibitor used to manage complement-mediated disorders. As a humanized IgG2/4 kappa monoclonal antibody, it binds with high affinity to complement protein C5, preventing its cleavage into pro-inflammatory fragments C5a and C5b. This blockade effectively halts the formation of the membrane attack complex (C5b-9), thereby reducing terminal complement-mediated inflammation, cell activation, and lysis. Ravulizumab is structurally derived from eculizumab, with enhanced pharmacokinetics that enable less frequent dosing.

In clinical and research settings, ravulizumab is a key therapeutic biomarker for monitoring and managing conditions such as paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and other disorders driven by complement dysregulation, including myasthenia gravis. Its ability to suppress intravascular hemolysis and thrombotic microangiopathy underscores its utility in modulating excessive immune responses and preventing long-term organ damage.

From a therapeutic drug monitoring (TDM) perspective, ravulizumab levels may be assessed to ensure consistent suppression of the complement pathway, optimize patient-specific dosage regimens, and reduce the risk of relapse or breakthrough hemolysis. Monitoring anti-drug antibodies (ADAs) and neutralizing antibody formation also supports improved drug efficacy, compliance, and reduced adverse immune reactions.

This product is manufactured in Turkey by Matriks Biotek.

Size 1 x 96 Well
Sensitivity 18.75 ng/mL
Dynamic Range 20-600 ng/mL
Incubation Time 70 minutes
Sample Type Serum, Plasma
Immunogen
Source Species
Specificity
Expression System
Clone
Group
Alpha Chain
Beta Chain
Peptide
Peptide Source
Format
Buffer
Concentration
Storage 2-8°C
Alternative Names Ravulizumab, Ultomiris, anti-C5 monoclonal antibody, long-acting complement C5 inhibitor, humanized IgG2/4 kappa antibody, C5-targeting biologic, eculizumab derivative, terminal complement pathway blocker, complement-mediated disorder therapy, PNH and aHUS biologic.
Instructions For Use https://eaglebio.com/wp-content/uploads/2025/07/RAV-FD-ULT-shikari-ravulizumab-elisa-instructions-for-use.pdf
MSDS https://eaglebio.com/wp-content/uploads/2025/07/RAV-FD-ULT-shikari-ravulizumab-elisa-sds.pdf

Product Citations